Condition
Limited-stage Small-cell Lung Cancer
Total Trials
5
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 5 trials
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
5Total
P 1 (1)
P 2 (3)
P 3 (1)
Trial Status
Not Yet Recruiting3
Recruiting1
Withdrawn1
Clinical Trials (5)
Showing 5 of 5 trials
NCT07242547Phase 2RecruitingPrimary
Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients
NCT07200154Phase 2Not Yet RecruitingPrimary
Adebrelimab Plus Chemoradiotherapy Followed by Adebrelimab Maintenance in Limited-Stage SCLC
NCT06427369Phase 1Withdrawn
An Investigational Scan (124I-hJAA-F11 PET/CT) for Diagnosing Lung Cancer
NCT06526624Phase 3Not Yet RecruitingPrimary
A Study of HS-20093 vs Active Surveillance in Limited-Stage Small Cell Lung Cancer
NCT06375109Phase 2Not Yet RecruitingPrimary
PD-L1/PD-1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone for the Neoadjuvant Treatment of Limited-stage SCLC
Showing all 5 trials